Stockscreener 앱 받기
3.20
4.55%
0.14
전일 마감가:
$3.06
열려 있는:
$3.1
하루 거래량:
426.78K
Relative Volume:
0.75
시가총액:
$335.58M
수익:
$45.44M
순이익/손실:
$-35.43M
주가수익비율:
-9.4118
EPS:
-0.34
순현금흐름:
$-25.39M
1주 성능:
-8.85%
1개월 성능:
-23.28%
6개월 성능:
-20.62%
1년 성능:
-23.83%
1일 변동 폭
$3.02
$3.245
1주일 범위
$2.76
$3.495
52주 변동 폭
$2.76
$5.26
맥스사이트 Stock (MXCT) Company Profile
명칭
Maxcyte Inc
전화
301-517-5556
주소
9713 KEY WEST AVENUE,, ROCKVILLE
MXCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
3.20 | 335.58M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
126.09 | 221.85B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
96.89 | 142.24B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
370.31 | 140.07B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
93.08 | 118.98B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
68.66 | 40.31B | 5.72B | 4.17B | 259.90M | 6.97 |
맥스사이트 Stock (MXCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-29 | 개시 | Craig Hallum | Buy |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-08-24 | 개시 | BTIG Research | Buy |
| 2021-08-24 | 개시 | Cowen | Outperform |
| 2021-08-24 | 개시 | Stephens | Overweight |
| 2021-08-24 | 개시 | Stifel | Buy |
| 2021-08-24 | 개시 | Wedbush | Outperform |
| 2021-08-24 | 개시 | William Blair | Outperform |
모두보기
맥스사이트 주식(MXCT)의 최신 뉴스
Stifel Nicolaus Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price - Defense World
What is William Blair’s Estimate for MaxCyte Q1 Earnings? - Defense World
MaxCyte files annual report with SEC By Investing.com - Investing.com Australia
MaxCyte core business revenue grows despite overall decline By Investing.com - Investing.com Australia
Stifel cuts MaxCyte stock price target to $9 from $11 By Investing.com - Investing.com Canada
Stifel cuts MaxCyte stock price target to $9 from $11 - Investing.com
MaxCyte stock touches 52-week low at $3.11 amid market challenges - Investing.com India
MaxCyte’s Promising Financial Outlook and Strategic Growth Justify Buy Rating - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2024 Earnings Call Transcript - Insider Monkey
MaxCyte price target lowered to $6 from $8 at BTIG - TipRanks
MaxCyte stock price target cut to $6 at BTIG By Investing.com - Investing.com South Africa
MaxCyte price target lowered to $9 from $11 at Stifel - TipRanks
MaxCyte stock price target cut to $6 at BTIG - Investing.com India
MaxCyte files annual report with SEC - Investing.com India
MaxCyte core business revenue grows despite overall decline - Investing.com India
Maxcyte Sees 2025 Core Revenue To Grow 8% To 15% -March 12, 2025 at 03:20 am EDT - Marketscreener.com
MaxCyte reports a return to core revenue growth in FY24 - DirectorsTalk Interviews
MaxCyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MaxCyte’s Strategic Expansion and Financial Resilience Drive Buy Rating - TipRanks
MaxCyte shares tumble as Q4 revenue plunges despite beating estimates By Investing.com - Investing.com Australia
MaxCyte shares tumble as Q4 revenue plunges despite beating estimates - Investing.com India
MaxCyte reports Q4 EPS (10c), consensus (12c) - TipRanks
MAXCYTE, INC. SEC 10-K Report - TradingView
MaxCyte Reports 2024 Financial Results with Core Growth - TipRanks
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance - The Manila Times
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 ... - Bluefield Daily Telegraph
MaxCyte (MXCT) Expected to Announce Quarterly Earnings on Tuesday - Defense World
MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments - MSN
MaxCyte Expands Stock Capital with New Issuance - TipRanks
MaxCyte, Inc.'s (LON:MXCT) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors - Simply Wall St
Institutional owners may take dramatic actions as MaxCyte, Inc.'s (LON:MXCT) recent 11% drop adds to one-year losses - Simply Wall St
MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MSN
Andrew Mancini, PhD's Profile Page - Technology Networks
263,833 Shares in MaxCyte, Inc. (NASDAQ:MXCT) Bought by Rice Hall James & Associates LLC - MarketBeat
TG Therapeutics advancing CAR T-cell therapy toward Phase 1 trial - Multiple Sclerosis News Today
MaxCyte Experiences Shift in Major Holdings by BlackRock - TipRanks
BlackRock Increases Stake in MaxCyte to 7.66% - TipRanks
Bio Buyout: MaxCyte Acquires SeQure - Law Street Media
BlackRock Adjusts Holdings in MaxCyte, Inc. - TipRanks
TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases - MSN
TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform - News-Medical.Net
TG Therapeutics Licenses Maxcyte Tech to Develop Cell Therapies for Autoimmune Disease - Genetic Engineering & Biotechnology News
MaxCyte Signs Licensing Deal With TG Therapeutics For Next-Gen Autoimmune Cell Therapies - Nasdaq
MaxCyte signs SPL deal with TG Therapeutics - ShareCast
MaxCyte Signs Platform License Deal With TG Therapeutics -February 12, 2025 at 05:07 am EST - Marketscreener.com
MaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programs - MSN
MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics -February 12, 2025 at 04:37 am EST - Marketscreener.com
MaxCyte and TG Therapeutics partner on next-gen cell therapy for MS - DirectorsTalk Interviews
MaxCyte Partners with TG Therapeutics for Autoimmune Cell Therapy - TipRanks
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - The Manila Times
Maxcyte Says Enters Strategic Platform License With TG Therapeutics -February 12, 2025 at 02:18 am EST - Marketscreener.com
맥스사이트 (MXCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
맥스사이트 주식 (MXCT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Johnston John Joseph | Director |
Jan 27 '25 |
Sale |
4.64 |
3,000 |
13,935 |
141,950 |
| Sandoval David I. | GENERAL COUNSEL |
Jan 13 '25 |
Sale |
4.54 |
4,466 |
20,272 |
41,447 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Sale |
4.01 |
3,000 |
12,021 |
141,950 |
0.57%
0.83%
자본화:
|
볼륨(24시간):